| Trial code |
Clinical progression |
Overall survival |
| |
Progression rate (%) |
HR (p-value) |
Mortality rate (%) |
HR (p –value) |
| MRC trial M0 subgroup
EORTC 30846 |
38 vs. 59
Not reported
|
Not reported (p<0,001)
Not reported |
59 vs. 70
61 vs. 62 |
Not reported (p=0,02)
1,23 (NS) |
| EPC (1) |
44 vs. 61 |
0,53 (p<0,0001) |
34 vs. 41 |
0,81(p=0,097) |
| EPC (2) |
29 vs. 32 |
0,81 (p=0,018) |
25 vs. 21 |
1,23 (p=0,050) |
| SAK 08/88 |
Not reported |
Not reported |
24 vs. 37 |
0,99(p=0,096) |
| EORTC 30891 |
Not reported |
Not reported |
52.2% vs. 57 |
1,25 (p=0,434) |
HR, Hazard ratio |
